DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
19.65
-0.19 (-0.96%)
At close: May 15, 2026, 4:00 PM EDT
19.25
-0.40 (-2.04%)
Pre-market: May 18, 2026, 7:09 AM EDT
DBV Technologies Revenue
DBV Technologies had revenue of $900.00K in the quarter ending March 31, 2026, with 12.50% growth. This brings the company's revenue in the last twelve months to $5.14M, up 69.44% year-over-year. In the year 2025, DBV Technologies had annual revenue of $5.64M with 35.77% growth.
Revenue (ttm)
$5.14M
Revenue Growth
+69.44%
P/S Ratio
200.96
Revenue / Employee
$35,627
Employees
161
Market Cap
1.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.64M | 1.49M | 35.77% |
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | 14.71M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AbCellera Biologics | 79.21M |
| Septerna | 72.26M |
| Zenas BioPharma | 10.00M |
| Aktis Oncology | 8.28M |
| Inventiva | 7.94M |
DBVT News
- 4 days ago - DBV Technologies S.A.: Combined General Meeting of June 3, 2026 - Finanz Nachrichten
- 4 days ago - Combined General Meeting of June 3, 2026 - GlobeNewsWire
- 5 days ago - DBV Technologies S.A.: DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq - Finanz Nachrichten
- 5 days ago - DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq - GlobeNewsWire
- 13 days ago - DBVT Reiterated by Guggenheim -- Price Target Maintained at $51.00 - GuruFocus
- 16 days ago - DBVT Maintained by Citizens -- Price Target Raised to $55.00 - GuruFocus
- 17 days ago - DBV Technologies price target raised to $55 from $47 at Citizens - TheFly
- 17 days ago - DBVT SWOT Analysis: Financial Challenges and Growth Potential Revealed in 10-Q Filing - GuruFocus